🇺🇸 FDA
Pipeline program

ALXN1850, ALXN1850 placebo product

ALXN1850-HPP-305

Phase 3 small_molecule active

Quick answer

ALXN1850, ALXN1850 placebo product for hypophosphatasia is a Phase 3 program (small_molecule) at Alexion Europe SAS with 1 ClinicalTrials.gov record(s).

Program details

Company
Alexion Europe SAS
Indication
hypophosphatasia
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials